APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

PD-L1 Biomarker Testing

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).

PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.

PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.

Selected research

Market Analysis & Forecast

Global PD-L1 Biomarker Testing Market Analysis and Forecast 2026-2032

Report ID 173895100231 December 2025197 pages

Choose your research edition.

Industry ResearchPD-L1 Biomarker Testing Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-L1 Biomarker Testing Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal PD-L1 Biomarker Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-L1 Biomarker Testing Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-L1 Biomarker Testing Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).

PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.

Read the full market overview

PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.

The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2019 is about 21.68%.

PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2019 is about 52.7%.

North Americas is the largest consumption place, with a consumption market share nearly 55.63% in 2019. Following North Americas, Europe is the second largest consumption place with the consumption market share of 26.7%.

Report Includes

This report presents an overview of global market for PD-L1 Biomarker Testing, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of PD-L1 Biomarker Testing, also provides the revenue of main regions and countries. Of the upcoming market potential for PD-L1 Biomarker Testing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the PD-L1 Biomarker Testing revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global PD-L1 Biomarker Testing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for PD-L1 Biomarker Testing revenue, projected growth trends, production technology, application and end-user industry.

PD-L1 Biomarker Testing Segment by Company

Agilent Technologies

Roche

Merck

Bristol-Myers Squibb

AstraZeneca

Ono Pharmaceutical

Regeneron

Innovent

Hengrui Medicine

Junshi Biosciences

PD-L1 Biomarker Testing Segment by Type

PD-L1 (22C3)

PD-L1(28-8)

PD-L1 (SP142)

PD-L1 (SP263)

Other

PD-L1 Biomarker Testing Segment by Application

Hospital

Diagnostic Center

Others

PD-L1 Biomarker Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-L1 Biomarker Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-L1 Biomarker Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-L1 Biomarker Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of PD-L1 Biomarker Testing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of PD-L1 Biomarker Testing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PD-L1 Biomarker Testing revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global PD-L1 Biomarker Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. PD-L1 (22C3) Major Player Table 3. PD-L1(28-8) Major Player Table 4. PD-L1 (SP142) Major Player Table 5. PD-L1 (SP263) Major Player Table 6. Other Major Player Table 7. Global PD-L1 Biomarker Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospital Major Player Table 9. Diagnostic Center Major Player Table 10. Others Major Player Table 11. PD-L1 Biomarker Testing Industry Trends Table 12. PD-L1 Biomarker Testing Industry Drivers Table 13. PD-L1 Biomarker Testing Industry Opportunities and Challenges Table 14. PD-L1 Biomarker Testing Industry Restraints Table 15. Global PD-L1 Biomarker Testing Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global PD-L1 Biomarker Testing Market Size by Region (2021-2026) & (US$ Million) Table 17. Global PD-L1 Biomarker Testing Market Share by Region (2021-2026) Table 18. Global PD-L1 Biomarker Testing Market Size by Region (2027-2032) & (US$ Million) Table 19. Global PD-L1 Biomarker Testing Market Share by Region (2027-2032) Table 20. Global PD-L1 Biomarker Testing Revenue by Players (US$ Million) & (2021-2026) Table 21. Global PD-L1 Biomarker Testing Revenue Market Share by Players (2021-2026) Table 22. Global PD-L1 Biomarker Testing Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global PD-L1 Biomarker Testing Key Players Headquarters & Area Served Table 24. Global PD-L1 Biomarker Testing Players, Product Type & Application Table 25. Global PD-L1 Biomarker Testing Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global PD-L1 Biomarker Testing by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global PD-L1 Biomarker Testing Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global PD-L1 Biomarker Testing Revenue by Type (2021-2026) & (US$ Million) Table 30. Global PD-L1 Biomarker Testing Revenue by Type (2027-2032) & (US$ Million) Table 31. Global PD-L1 Biomarker Testing Revenue Market Share by Type (2021-2026) Table 32. Global PD-L1 Biomarker Testing Revenue Market Share by Type (2027-2032) Table 33. Global PD-L1 Biomarker Testing Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global PD-L1 Biomarker Testing Revenue by Application (2021-2026) & (US$ Million) Table 35. Global PD-L1 Biomarker Testing Revenue by Application (2027-2032) & (US$ Million) Table 36. Global PD-L1 Biomarker Testing Revenue Market Share by Application (2021-2026) Table 37. Global PD-L1 Biomarker Testing Revenue Market Share by Application (2027-2032) Table 38. Agilent Technologies Company Information Table 39. Agilent Technologies Business Overview Table 40. Agilent Technologies PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Agilent Technologies PD-L1 Biomarker Testing Product Portfolio Table 42. Agilent Technologies Recent Development Table 43. Roche Company Information Table 44. Roche Business Overview Table 45. Roche PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Roche PD-L1 Biomarker Testing Product Portfolio Table 47. Roche Recent Development Table 48. Merck Company Information Table 49. Merck Business Overview Table 50. Merck PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Merck PD-L1 Biomarker Testing Product Portfolio Table 52. Merck Recent Development Table 53. Bristol-Myers Squibb Company Information Table 54. Bristol-Myers Squibb Business Overview Table 55. Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Bristol-Myers Squibb PD-L1 Biomarker Testing Product Portfolio Table 57. Bristol-Myers Squibb Recent Development Table 58. AstraZeneca Company Information Table 59. AstraZeneca Business Overview Table 60. AstraZeneca PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. AstraZeneca PD-L1 Biomarker Testing Product Portfolio Table 62. AstraZeneca Recent Development Table 63. Ono Pharmaceutical Company Information Table 64. Ono Pharmaceutical Business Overview Table 65. Ono Pharmaceutical PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Ono Pharmaceutical PD-L1 Biomarker Testing Product Portfolio Table 67. Ono Pharmaceutical Recent Development Table 68. Regeneron Company Information Table 69. Regeneron Business Overview Table 70. Regeneron PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Regeneron PD-L1 Biomarker Testing Product Portfolio Table 72. Regeneron Recent Development Table 73. Innovent Company Information Table 74. Innovent Business Overview Table 75. Innovent PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Innovent PD-L1 Biomarker Testing Product Portfolio Table 77. Innovent Recent Development Table 78. Hengrui Medicine Company Information Table 79. Hengrui Medicine Business Overview Table 80. Hengrui Medicine PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Hengrui Medicine PD-L1 Biomarker Testing Product Portfolio Table 82. Hengrui Medicine Recent Development Table 83. Junshi Biosciences Company Information Table 84. Junshi Biosciences Business Overview Table 85. Junshi Biosciences PD-L1 Biomarker Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Junshi Biosciences PD-L1 Biomarker Testing Product Portfolio Table 87. Junshi Biosciences Recent Development Table 88. North America PD-L1 Biomarker Testing Revenue by Type (2021-2026) & (US$ Million) Table 89. North America PD-L1 Biomarker Testing Revenue by Type (2027-2032) & (US$ Million) Table 90. North America PD-L1 Biomarker Testing Revenue by Application (2021-2026) & (US$ Million) Table 91. North America PD-L1 Biomarker Testing Revenue by Application (2027-2032) & (US$ Million) Table 92. North America PD-L1 Biomarker Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 93. North America PD-L1 Biomarker Testing Revenue by Country (2021-2026) & (US$ Million) Table 94. North America PD-L1 Biomarker Testing Revenue by Country (US$ Million) & (2027-2032) Table 95. Europe PD-L1 Biomarker Testing Revenue by Type (2021-2026) & (US$ Million) Table 96. Europe PD-L1 Biomarker Testing Revenue by Type (2027-2032) & (US$ Million) Table 97. Europe PD-L1 Biomarker Testing Revenue by Application (2021-2026) & (US$ Million) Table 98. Europe PD-L1 Biomarker Testing Revenue by Application (2027-2032) & (US$ Million) Table 99. Europe PD-L1 Biomarker Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. Europe PD-L1 Biomarker Testing Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe PD-L1 Biomarker Testing Revenue by Country (US$ Million) & (2027-2032) Table 102. China PD-L1 Biomarker Testing Revenue by Type (2021-2026) & (US$ Million) Table 103. China PD-L1 Biomarker Testing Revenue by Type (2027-2032) & (US$ Million) Table 104. China PD-L1 Biomarker Testing Revenue by Application (2021-2026) & (US$ Million) Table 105. China PD-L1 Biomarker Testing Revenue by Application (2027-2032) & (US$ Million) Table 106. Asia PD-L1 Biomarker Testing Revenue by Type (2021-2026) & (US$ Million) Table 107. Asia PD-L1 Biomarker Testing Revenue by Type (2027-2032) & (US$ Million) Table 108. Asia PD-L1 Biomarker Testing Revenue by Application (2021-2026) & (US$ Million) Table 109. Asia PD-L1 Biomarker Testing Revenue by Application (2027-2032) & (US$ Million) Table 110. Asia PD-L1 Biomarker Testing Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 111. Asia PD-L1 Biomarker Testing Revenue by Region (US$ Million) & (2021-2026) Table 112. Asia PD-L1 Biomarker Testing Revenue by Region (US$ Million) & (2027-2032) Table 113. SAMEA PD-L1 Biomarker Testing Revenue by Type (2021-2026) & (US$ Million) Table 114. SAMEA PD-L1 Biomarker Testing Revenue by Type (2027-2032) & (US$ Million) Table 115. SAMEA PD-L1 Biomarker Testing Revenue by Application (2021-2026) & (US$ Million) Table 116. SAMEA PD-L1 Biomarker Testing Revenue by Application (2027-2032) & (US$ Million) Table 117. SAMEA PD-L1 Biomarker Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. SAMEA PD-L1 Biomarker Testing Revenue by Country (2021-2026) & (US$ Million) Table 119. SAMEA PD-L1 Biomarker Testing Revenue by Country (US$ Million) & (2027-2032) Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. PD-L1 Biomarker Testing Image Figure 2. Global PD-L1 Biomarker Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PD-L1 Biomarker Testing Market Size Share 2021 VS 2025 VS 2032 Figure 4. PD-L1 (22C3) Image Figure 5. PD-L1(28-8) Image Figure 6. PD-L1 (SP142) Image Figure 7. PD-L1 (SP263) Image Figure 8. Other Image Figure 9. Global PD-L1 Biomarker Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global PD-L1 Biomarker Testing Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospital Image Figure 12. Diagnostic Center Image Figure 13. Others Image Figure 14. Global PD-L1 Biomarker Testing Market Size (US$ Million) & (2021-2032) Figure 15. Global PD-L1 Biomarker Testing Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global PD-L1 Biomarker Testing Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global PD-L1 Biomarker Testing Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global PD-L1 Biomarker Testing Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global PD-L1 Biomarker Testing Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global PD-L1 Biomarker Testing Revenue Market Share by Type (2021-2032) Figure 22. Global PD-L1 Biomarker Testing Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global PD-L1 Biomarker Testing Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global PD-L1 Biomarker Testing Revenue Market Share by Application (2021-2032) Figure 25. North America PD-L1 Biomarker Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America PD-L1 Biomarker Testing Revenue Share by Type (2021-2032) Figure 27. North America PD-L1 Biomarker Testing Revenue Share by Application (2021-2032) Figure 28. North America PD-L1 Biomarker Testing Revenue Share by Country (2021-2032) Figure 29. United States PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe PD-L1 Biomarker Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe PD-L1 Biomarker Testing Revenue Share by Type (2021-2032) Figure 34. Europe PD-L1 Biomarker Testing Revenue Share by Application (2021-2032) Figure 35. Europe PD-L1 Biomarker Testing Revenue Share by Country (2021-2032) Figure 36. Germany PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China PD-L1 Biomarker Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China PD-L1 Biomarker Testing Revenue Share by Type (2021-2032) Figure 46. China PD-L1 Biomarker Testing Revenue Share by Application (2021-2032) Figure 47. Asia PD-L1 Biomarker Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia PD-L1 Biomarker Testing Revenue Share by Type (2021-2032) Figure 49. Asia PD-L1 Biomarker Testing Revenue Share by Application (2021-2032) Figure 50. Asia PD-L1 Biomarker Testing Revenue Share by Region (2021-2032) Figure 51. Japan PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA PD-L1 Biomarker Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA PD-L1 Biomarker Testing Revenue Share by Type (2021-2032) Figure 59. SAMEA PD-L1 Biomarker Testing Revenue Share by Application (2021-2032) Figure 60. SAMEA PD-L1 Biomarker Testing Revenue Share by Country (2021-2032) Figure 61. Brazil PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt PD-L1 Biomarker Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • PD-L1 (22C3)
  • PD-L1(28-8)
  • PD-L1 (SP142)
  • PD-L1 (SP263)
  • Other
Applications
  • Hospital
  • Diagnostic Center
  • Others
Companies covered
  • Agilent Technologies
  • Roche
  • Merck
  • Bristol-Myers Squibb
  • AstraZeneca
  • Ono Pharmaceutical
  • Regeneron
  • Innovent
  • Hengrui Medicine
  • Junshi Biosciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 PD-L1 Biomarker Testing Market by Type
  3. 1.2.1 Global PD-L1 Biomarker Testing Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 PD-L1 (22C3)
  5. 1.2.3 PD-L1(28-8)
  6. 1.2.4 PD-L1 (SP142)
  7. 1.2.5 PD-L1 (SP263)
  8. 1.2.6 Other
  9. 1.3 PD-L1 Biomarker Testing Market by Application
  10. 1.3.1 Global PD-L1 Biomarker Testing Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital
  12. 1.3.3 Diagnostic Center
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 PD-L1 Biomarker Testing Market Dynamics
  1. 2.1 PD-L1 Biomarker Testing Industry Trends
  2. 2.2 PD-L1 Biomarker Testing Industry Drivers
  3. 2.3 PD-L1 Biomarker Testing Industry Opportunities and Challenges
  4. 2.4 PD-L1 Biomarker Testing Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global PD-L1 Biomarker Testing Market Perspective (2021-2032)
  2. 3.2 Global PD-L1 Biomarker Testing Growth Trends by Region
  3. 3.2.1 Global PD-L1 Biomarker Testing Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global PD-L1 Biomarker Testing Market Size by Region (2021-2026)
  5. 3.2.3 Global PD-L1 Biomarker Testing Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global PD-L1 Biomarker Testing Revenue by Players
  2. 4.1.1 Global PD-L1 Biomarker Testing Revenue by Players (2021-2026)
  3. 4.1.2 Global PD-L1 Biomarker Testing Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global PD-L1 Biomarker Testing Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global PD-L1 Biomarker Testing Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global PD-L1 Biomarker Testing Key Players Headquarters & Area Served
  7. 4.4 Global PD-L1 Biomarker Testing Players, Product Type & Application
  8. 4.5 Global PD-L1 Biomarker Testing Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global PD-L1 Biomarker Testing Market CR5 and HHI
  11. 4.6.3 2025 PD-L1 Biomarker Testing Tier 1, Tier 2, and Tier 3
5 PD-L1 Biomarker Testing Market Size by Type
  1. 5.1 Global PD-L1 Biomarker Testing Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global PD-L1 Biomarker Testing Revenue by Type (2021-2032)
  3. 5.3 Global PD-L1 Biomarker Testing Revenue Market Share by Type (2021-2032)
6 PD-L1 Biomarker Testing Market Size by Application
  1. 6.1 Global PD-L1 Biomarker Testing Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global PD-L1 Biomarker Testing Revenue by Application (2021-2032)
  3. 6.3 Global PD-L1 Biomarker Testing Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Agilent Technologies
  2. 7.1.1 Agilent Technologies Company Information
  3. 7.1.2 Agilent Technologies Business Overview
  4. 7.1.3 Agilent Technologies PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Agilent Technologies PD-L1 Biomarker Testing Product Portfolio
  6. 7.1.5 Agilent Technologies Recent Developments
  7. 7.2 Roche
  8. 7.2.1 Roche Company Information
  9. 7.2.2 Roche Business Overview
  10. 7.2.3 Roche PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Roche PD-L1 Biomarker Testing Product Portfolio
  12. 7.2.5 Roche Recent Developments
  13. 7.3 Merck
  14. 7.3.1 Merck Company Information
  15. 7.3.2 Merck Business Overview
  16. 7.3.3 Merck PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck PD-L1 Biomarker Testing Product Portfolio
  18. 7.3.5 Merck Recent Developments
  19. 7.4 Bristol-Myers Squibb
  20. 7.4.1 Bristol-Myers Squibb Company Information
  21. 7.4.2 Bristol-Myers Squibb Business Overview
  22. 7.4.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bristol-Myers Squibb PD-L1 Biomarker Testing Product Portfolio
  24. 7.4.5 Bristol-Myers Squibb Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca PD-L1 Biomarker Testing Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 Ono Pharmaceutical
  32. 7.6.1 Ono Pharmaceutical Company Information
  33. 7.6.2 Ono Pharmaceutical Business Overview
  34. 7.6.3 Ono Pharmaceutical PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Ono Pharmaceutical PD-L1 Biomarker Testing Product Portfolio
  36. 7.6.5 Ono Pharmaceutical Recent Developments
  37. 7.7 Regeneron
  38. 7.7.1 Regeneron Company Information
  39. 7.7.2 Regeneron Business Overview
  40. 7.7.3 Regeneron PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Regeneron PD-L1 Biomarker Testing Product Portfolio
  42. 7.7.5 Regeneron Recent Developments
  43. 7.8 Innovent
  44. 7.8.1 Innovent Company Information
  45. 7.8.2 Innovent Business Overview
  46. 7.8.3 Innovent PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Innovent PD-L1 Biomarker Testing Product Portfolio
  48. 7.8.5 Innovent Recent Developments
  49. 7.9 Hengrui Medicine
  50. 7.9.1 Hengrui Medicine Company Information
  51. 7.9.2 Hengrui Medicine Business Overview
  52. 7.9.3 Hengrui Medicine PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Hengrui Medicine PD-L1 Biomarker Testing Product Portfolio
  54. 7.9.5 Hengrui Medicine Recent Developments
  55. 7.10 Junshi Biosciences
  56. 7.10.1 Junshi Biosciences Company Information
  57. 7.10.2 Junshi Biosciences Business Overview
  58. 7.10.3 Junshi Biosciences PD-L1 Biomarker Testing Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Junshi Biosciences PD-L1 Biomarker Testing Product Portfolio
  60. 7.10.5 Junshi Biosciences Recent Developments
8 North America
  1. 8.1 North America PD-L1 Biomarker Testing Revenue (2021-2032)
  2. 8.2 North America PD-L1 Biomarker Testing Revenue by Type (2021-2032)
  3. 8.2.1 North America PD-L1 Biomarker Testing Revenue by Type (2021-2026)
  4. 8.2.2 North America PD-L1 Biomarker Testing Revenue by Type (2027-2032)
  5. 8.3 North America PD-L1 Biomarker Testing Revenue Share by Type (2021-2032)
  6. 8.4 North America PD-L1 Biomarker Testing Revenue by Application (2021-2032)
  7. 8.4.1 North America PD-L1 Biomarker Testing Revenue by Application (2021-2026)
  8. 8.4.2 North America PD-L1 Biomarker Testing Revenue by Application (2027-2032)
  9. 8.5 North America PD-L1 Biomarker Testing Revenue Share by Application (2021-2032)
  10. 8.6 North America PD-L1 Biomarker Testing Revenue by Country
  11. 8.6.1 North America PD-L1 Biomarker Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America PD-L1 Biomarker Testing Revenue by Country (2021-2026)
  13. 8.6.3 North America PD-L1 Biomarker Testing Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe PD-L1 Biomarker Testing Revenue (2021-2032)
  2. 9.2 Europe PD-L1 Biomarker Testing Revenue by Type (2021-2032)
  3. 9.2.1 Europe PD-L1 Biomarker Testing Revenue by Type (2021-2026)
  4. 9.2.2 Europe PD-L1 Biomarker Testing Revenue by Type (2027-2032)
  5. 9.3 Europe PD-L1 Biomarker Testing Revenue Share by Type (2021-2032)
  6. 9.4 Europe PD-L1 Biomarker Testing Revenue by Application (2021-2032)
  7. 9.4.1 Europe PD-L1 Biomarker Testing Revenue by Application (2021-2026)
  8. 9.4.2 Europe PD-L1 Biomarker Testing Revenue by Application (2027-2032)
  9. 9.5 Europe PD-L1 Biomarker Testing Revenue Share by Application (2021-2032)
  10. 9.6 Europe PD-L1 Biomarker Testing Revenue by Country
  11. 9.6.1 Europe PD-L1 Biomarker Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe PD-L1 Biomarker Testing Revenue by Country (2021-2026)
  13. 9.6.3 Europe PD-L1 Biomarker Testing Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China PD-L1 Biomarker Testing Revenue (2021-2032)
  2. 10.2 China PD-L1 Biomarker Testing Revenue by Type (2021-2032)
  3. 10.2.1 China PD-L1 Biomarker Testing Revenue by Type (2021-2026)
  4. 10.2.2 China PD-L1 Biomarker Testing Revenue by Type (2027-2032)
  5. 10.3 China PD-L1 Biomarker Testing Revenue Share by Type (2021-2032)
  6. 10.4 China PD-L1 Biomarker Testing Revenue by Application (2021-2032)
  7. 10.4.1 China PD-L1 Biomarker Testing Revenue by Application (2021-2026)
  8. 10.4.2 China PD-L1 Biomarker Testing Revenue by Application (2027-2032)
  9. 10.5 China PD-L1 Biomarker Testing Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia PD-L1 Biomarker Testing Revenue (2021-2032)
  2. 11.2 Asia PD-L1 Biomarker Testing Revenue by Type (2021-2032)
  3. 11.2.1 Asia PD-L1 Biomarker Testing Revenue by Type (2021-2026)
  4. 11.2.2 Asia PD-L1 Biomarker Testing Revenue by Type (2027-2032)
  5. 11.3 Asia PD-L1 Biomarker Testing Revenue Share by Type (2021-2032)
  6. 11.4 Asia PD-L1 Biomarker Testing Revenue by Application (2021-2032)
  7. 11.4.1 Asia PD-L1 Biomarker Testing Revenue by Application (2021-2026)
  8. 11.4.2 Asia PD-L1 Biomarker Testing Revenue by Application (2027-2032)
  9. 11.5 Asia PD-L1 Biomarker Testing Revenue Share by Application (2021-2032)
  10. 11.6 Asia PD-L1 Biomarker Testing Revenue by Country
  11. 11.6.1 Asia PD-L1 Biomarker Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia PD-L1 Biomarker Testing Revenue by Country (2021-2026)
  13. 11.6.3 Asia PD-L1 Biomarker Testing Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA PD-L1 Biomarker Testing Revenue (2021-2032)
  2. 12.2 SAMEA PD-L1 Biomarker Testing Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA PD-L1 Biomarker Testing Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA PD-L1 Biomarker Testing Revenue by Type (2027-2032)
  5. 12.3 SAMEA PD-L1 Biomarker Testing Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA PD-L1 Biomarker Testing Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA PD-L1 Biomarker Testing Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA PD-L1 Biomarker Testing Revenue by Application (2027-2032)
  9. 12.5 SAMEA PD-L1 Biomarker Testing Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA PD-L1 Biomarker Testing Revenue by Country
  11. 12.6.1 SAMEA PD-L1 Biomarker Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA PD-L1 Biomarker Testing Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA PD-L1 Biomarker Testing Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst